Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes.
about
Efficacy of Osteoporosis Therapies in Diabetic Patients.Bone and glucose metabolism: a two-way streetRaloxifene prevents skeletal fragility in adult female Zucker Diabetic Sprague-Dawley rats.Estrogens and the diabetic kidneyRenoprotective effects of a selective estrogen receptor modulator, raloxifene, in an animal model of diabetic nephropathySex hormones, insulin sensitivity, and diabetes mellitus.Selective estrogen receptor modulation in pancreatic β-cells and the prevention of type 2 diabetesThe role of estrogens in control of energy balance and glucose homeostasis.Circulating estrone levels are associated prospectively with diabetes risk in men of the Framingham Heart Study.An old friend in a new light: the role of osteocalcin in energy metabolism.Bone as an endocrine organ relevant to diabetes.Neurocognitive, Neuroprotective, and Cardiometabolic Effects of Raloxifene: Potential for Improving Therapeutic Outcomes in Schizophrenia.The effect of selective estrogen receptor modulators on type 2 diabetes onset in women: Basic and clinical insights.Risk factors for cardiovascular disease in women with diabetes.Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials.Effects of raloxifene on body fat distribution and lipid profile in healthy post-menopausal women.Bazedoxifene and conjugated estrogen prevent diet-induced obesity, hepatic steatosis, and type 2 diabetes in mice without impacting the reproductive tract.Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: subgroup analysis of a double-blind randomized controlled trial.
P2860
Q30248776-A19951DB-9916-493C-86E6-4F0CDF65211FQ34160465-1CBCDD02-10AF-4AC5-A1B2-ECD210A24E68Q34227038-4163AE2A-6376-44F0-B589-F7683F833AC7Q35228627-F82D2AF6-B5C7-4F58-9921-67A632456186Q35230897-9A5738A3-04C8-473A-86C5-976B8408C14BQ35757562-4F651B18-C5BB-49CC-B19A-30E48FC0500DQ36094776-C0CA52E0-C9D0-443C-A0A1-6E93865C16BBQ36864744-BB995635-AC48-4C16-B1CE-375EF5F6D863Q37106511-56389E5B-9E83-42EA-BB88-D7FD44BEC01FQ37942705-D8D7A453-ED83-46C0-B4F5-4DA5DDE95876Q38262674-37A0B2CC-8C0A-46C0-BCC8-692C700A4370Q38837641-AEA47732-590B-4697-8D92-EFBAEFEF03E2Q39129668-C9DE921D-A1BF-4B84-9C3A-8362B060225CQ42921285-833CE66C-4C56-49D0-90A4-8060295C7CA6Q43461322-FDF44DDD-C968-41A1-A2D6-7FB0B39100B2Q46746525-3CBE473F-48D6-4470-8039-A8BAA513412EQ51133579-B1927078-46BF-4AF9-B4DB-1CB2DAD5EE71Q51194691-EE2F3D1D-927A-4505-A8A1-69A2E7FF4102
P2860
Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Post hoc analysis of data from ...... h and without type 2 diabetes.
@ast
Post hoc analysis of data from ...... h and without type 2 diabetes.
@en
type
label
Post hoc analysis of data from ...... h and without type 2 diabetes.
@ast
Post hoc analysis of data from ...... h and without type 2 diabetes.
@en
prefLabel
Post hoc analysis of data from ...... h and without type 2 diabetes.
@ast
Post hoc analysis of data from ...... h and without type 2 diabetes.
@en
P2093
P1476
Post hoc analysis of data from ...... h and without type 2 diabetes.
@en
P2093
Andreas Sashegyi
Kathryn A Krueger
Kristine E Ensrud
Kristine Harper
Pamela W Anderson
Timothy M Mason
P304
P356
10.1016/S0149-2918(03)80114-5
P577
2003-03-01T00:00:00Z